Human Urinary Kallidinogenase is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include General Hospital of Shenyang Military Region (1) and China-Japan Union Hospital (1). Registered phases: Phase 2 and Not applicable. Conditions studied include Ischemic Stroke; Acute Ischemic Stroke.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07283159 | Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS) (ClinicalTrials.gov ↗) Ischemic Stroke |
Phase 2 | Recruiting |
| NCT07483281 | Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (ClinicalTrials.gov ↗) Acute Ischemic Stroke |
Not applicable | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ischemic Stroke | 1 |
| Acute Ischemic Stroke | 1 |
| Lead sponsor | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 1 |
| China-Japan Union Hospital | 1 |
| Register | Human Urinary Kallidinogenase trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Human Urinary Kallidinogenase works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Human Urinary Kallidinogenase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.